ERBB2 and breast cancer: Further work is needed to better understand the pathophysiology of T-Dxd-associated ILD/pneumonitis along with the delineation of risk factors, prevention, and treatment measures, ultimately to improve the safety profile of T-Dxd for treating HER2-low BC.